6:36 AM
Mar 10, 2018
 |  BC Extra  |  Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Editor's Note: This article was updated on Mar 12, 2018 at 12:14 PM PDT

Armed with cardiovascular outcomes data for Praluent alirocumab and a fresh cost-effectiveness analysis from the Institute for Clinical and Economic Review (ICER), Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have a proposition for payers: reduce barriers to access in high-risk patients and the partners will offer up to a 69% discount to the PCSK9 inhibitor’s list price.

“We commit to working with all health plans that agree to remove access barriers for high-risk patients to offer a more cost-effective net price for Praluent,” said Regeneron President and CEO Leonard Schleifer in a statement issued March 10 following the results of ODYSSEY OUTCOMES study.

Data from the 18,924-patient trial showed Praluent given on top of statins lowered the risk of major adverse cardiovascular events (MACE) by 15% (HR=0.85, CI: 0.78, 0.93, p=0.0003). The MACE composite endpoint includes patients who experienced a heart attack, stroke, death from coronary heart disease (CHD) or unstable angina requiring hospitalization. The data were presented at the American College of Cardiology (ACC) meeting.

Praluent was also associated with a lower risk of all-cause mortality (HR=0.85, CI: 0.73, 0.98, p=0.026). In a...

Read the full 904 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD